Co-administration of Shingles and RSV Vaccines Produces Positive …
WEB5 days ago — GSK plc recently announced topline Phase 3 clinical trial data for a combination regimen of two of its vaccines: the RSV vaccine Arexvy and Shingrix, a market-leading shingles shot. While GSK did not provide specific clinical trial (NCT05966090) data in its September 18, 2024 announcement, the company did confirm that co-administering Arexvy with Shingrix resulted in a “non-inferior immune ...
Major study finds new shingles vaccine could lower risk of dementia
WEBJul 26, 2024 — The findings: Shingrix was associated with 17% lower risk of dementia than Zostavax. Shingrix was also associated with 23-27% lower risk of dementia than with the other vaccines compared. This equals 5 to 9 more months lived without dementia. The benefits of Shingrix were found in both sexes but were greater in women.
Shingles vaccines may reduce dementia risk, two large new studies ... - CNN
WEBJul 30, 2024 — CNN — Two new studies suggest that getting a vaccine to protect against a painful case of shingles may be beneficial for memory, too. An estimated 98% of US adults have had chickenpox and are at...
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
WEB5 days ago — ILMN. BVS. GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in ...
New shingles vaccine could reduce risk of dementia
WEBJul 25, 2024 — The new recombinant shingles vaccine ‘Shingrix’ is associated with a reduced risk of dementia compared to an earlier shingles vaccine, according to a major new study published in Nature Medicine. It is also more protective …
Shingles Vaccine Recommendations | Shingles (Herpes Zoster) | CDC
WEBJul 19, 2024 — CDC recommends Shingrix (recombinant zoster vaccine or RZV) for the prevention of herpes zoster (shingles) and related complications. This page summarizes CDC's current shingles vaccine recommendations.
Two-dose shingles vaccine is still highly effective after four years
WEBApr 1, 2024 — The CDC recommends adults ages 50 and older get two doses of the recombinant zoster vaccine (Shingrix), with the doses separated by two to six months, to prevent shingles. But how long can it offer protection?
New long-term data show SHINGRIX continues to provide high
WEBApr 17, 2024 — GSK plc (LSE/NYSE: GSK) today announced positive data from the ZOSTER-049 long-term follow-up phase III trial which followed participants for up to approximately 11 years following initial vaccination with SHINGRIX (Recombinant Zoster Vaccine or RZV).
New data show Shingrix can provide at least 10 years of ... - GSK
WEBOct 19, 2022 — GSK plc (LSE/NYSE: GSK) today announced positive interim results from the ZOSTER-049 extension study showing that overall Shingrix (Zoster Vaccine Recombinant, Adjuvanted) can provide at least a decade of protection against shingles (herpes zoster) after initial vaccination.
Pfizer and BioNTech Initiate Phase 1/2 Study of First mRNA-based ...
WEBFeb 10, 2023 — NEW YORK and MAINZ, GERMANY, FEBRUARY 10, 2023 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies’ mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the varicel...
Skip to content